Credit Suisse’s Agios Pharmaceuticals AGIO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | $3.26M | Buy |
111,632
+2,438
| +2% | +$65.3K | ﹤0.01% | 1553 |
|
|
2023
Q4 | $2.43M | Buy |
109,194
+1,533
| +1% | +$34.4K | ﹤0.01% | 1770 |
|
|
2023
Q3 | $2.66M | Sell |
107,661
-13,104
| -11% | -$347K | ﹤0.01% | 1647 |
|
|
2023
Q2 | $3.42M | Buy |
120,765
+18,334
| +18% | +$456K | ﹤0.01% | 1581 |
|
|
2023
Q1 | $2.35M | Buy |
102,431
+5,911
| +6% | +$157K | ﹤0.01% | 1766 |
|
|
2022
Q4 | $2.71M | Buy |
96,520
+8,344
| +9% | +$235K | ﹤0.01% | 1710 |
|
|
2022
Q3 | $2.49M | Buy |
88,176
+12,901
| +17% | +$346K | ﹤0.01% | 1705 |
|
|
2022
Q2 | $1.67M | Sell |
75,275
-7,528
| -9% | -$170K | ﹤0.01% | 2039 |
|
|
2022
Q1 | $2.41M | Sell |
82,803
-860
| -1% | -$26.3K | ﹤0.01% | 1956 |
|
|
2021
Q4 | $2.75M | Sell |
83,663
-596
| -0.7% | -$24K | ﹤0.01% | 2529 |
|
|
2021
Q3 | $3.89M | Buy |
84,259
+426
| +0.5% | +$20.6K | ﹤0.01% | 2261 |
|
|
2021
Q2 | $4.62M | Sell |
83,833
-25,105
| -23% | -$1.4M | ﹤0.01% | 2147 |
|
|
2021
Q1 | $5.63M | Sell |
108,938
-33,913
| -24% | -$1.68M | ﹤0.01% | 1982 |
|
|
2020
Q4 | $6.19M | Buy |
142,851
+21,538
| +18% | +$852K | ﹤0.01% | 1929 |
|
|
2020
Q3 | $4.25M | Buy |
121,313
+11,173
| +10% | +$490K | ﹤0.01% | 1897 |
|
|
2020
Q2 | $5.89M | Buy |
110,140
+21,463
| +24% | +$994K | ﹤0.01% | 1605 |
|
|
2020
Q1 | $3.15M | Sell |
88,677
-15,521
| -15% | -$717K | ﹤0.01% | 1813 |
|
|
2019
Q4 | $4.98M | Buy |
104,198
+67,215
| +182% | +$2.54M | ﹤0.01% | 1883 |
|
|
2019
Q3 | $1.2M | Sell |
36,983
-10,861
| -23% | -$450K | ﹤0.01% | 2886 |
|
|
2019
Q2 | $2.39M | Buy |
47,844
+10,673
| +29% | +$570K | ﹤0.01% | 2322 |
|
|
2019
Q1 | $2.51M | Sell |
37,171
-5,664
| -13% | -$330K | ﹤0.01% | 2210 |
|
|
2018
Q4 | $1.97M | Buy |
42,835
+9,345
| +28% | +$577K | ﹤0.01% | 2251 |
|
|
2018
Q3 | $2.58M | Sell |
33,490
-1,956
| -6% | -$157K | ﹤0.01% | 2176 |
|
|
2018
Q2 | $2.99M | Sell |
35,446
-9,225
| -21% | -$804K | ﹤0.01% | 2131 |
|
|
2018
Q1 | $3.65M | Buy |
44,671
+10,693
| +31% | +$826K | ﹤0.01% | 1934 |
|
|
2017
Q4 | $1.94M | Sell |
33,978
-55,189
| -62% | -$3.47M | ﹤0.01% | 2457 |
|
|
2017
Q3 | $5.95M | Sell |
89,167
-52,563
| -37% | -$3.16M | 0.01% | 1640 |
|
|
2017
Q2 | $7.29M | Sell |
141,730
-30,735
| -18% | -$1.57M | 0.01% | 1389 |
|
|
2017
Q1 | $10.1M | Buy |
172,465
+44,332
| +35% | +$2.13M | 0.01% | 1217 |
|
|
2016
Q4 | $5.35M | Buy |
128,133
+5,784
| +5% | +$303K | 0.01% | 1598 |
|
|
2016
Q3 | $6.46M | Buy |
122,349
+22,462
| +22% | +$978K | 0.01% | 1467 |
|
|
2016
Q2 | $4.18M | Sell |
99,887
-33,854
| -25% | -$1.67M | ﹤0.01% | 1763 |
|
|
2016
Q1 | $5.43M | Buy |
133,741
+81,313
| +155% | +$3.48M | 0.01% | 1464 |
|
|
2015
Q4 | $3.4M | Buy |
52,428
+978
| +2% | +$64.1K | ﹤0.01% | 1883 |
|
|
2015
Q3 | $3.63M | Sell |
51,450
-36,643
| -42% | -$3.58M | ﹤0.01% | 1805 |
|
|
2015
Q2 | $9.79M | Buy |
88,093
+34,494
| +64% | +$3.72M | 0.01% | 1265 |
|
|
2015
Q1 | $5.05M | Buy |
53,599
+13,652
| +34% | +$1.53M | 0.01% | 1658 |
|
|
2014
Q4 | $4.47M | Sell |
39,947
-13,407
| -25% | -$1.2M | ﹤0.01% | 1856 |
|
|
2014
Q3 | $3.27M | Buy |
53,354
+39,419
| +283% | +$1.7M | ﹤0.01% | 2094 |
|
|
2014
Q2 | $639K | Sell |
13,935
-8,652
| -38% | -$353K | ﹤0.01% | 3658 |
|
|
2014
Q1 | $884K | Buy |
22,587
+11,430
| +102% | +$382K | ﹤0.01% | 3236 |
|
|
2013
Q4 | $267K | Sell |
11,157
-1,313
| -11% | -$29.9K | ﹤0.01% | 4161 |
|
|
2013
Q3 | $349K | Buy |
+12,470
| New | +$344K | ﹤0.01% | 3708 |
|
Other funds holding AGIO
FCM
BG
AC
EAM
Credit Suisse's AGIO Position: Q1 2024 in Review
Credit Suisse increased its Agios Pharmaceuticals (AGIO) stake by 2.2% in Q1 2024, buying an estimated $65.3K and bringing the position to 111,632 shares worth $3.26M. The position accounts for ﹤0.01% of the portfolio, ranked #1553.
Credit Suisse first reported a position in AGIO in Q3 2013 and has held it in 43 quarters since. The position peaked at $10.1M in Q1 2017. 187 funds tracked by Wall St. Rank hold AGIO as of Q1 2024.
- Credit Suisse held 111,632 shares of Agios Pharmaceuticals worth $3.26M as of Q1 2024.
- Credit Suisse bought 2,438 Agios Pharmaceuticals shares in Q1 2024, an estimated $65.3K.
- Agios Pharmaceuticals made up ﹤0.01% of Credit Suisse's portfolio in Q1 2024, its #1553 holding.
- Credit Suisse first reported a position in Agios Pharmaceuticals in Q3 2013 and has held it in 43 quarters since.
- Credit Suisse's Agios Pharmaceuticals position peaked at $10.1M in Q1 2017.
- 187 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q1 2024.
Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.